Pregabalin carries an unusually broad set of warnings for a drug that many people assume is milder than traditional painkillers or anti-anxiety medications. Originally approved for nerve pain, seizures, and generalized anxiety (in some countries), it has since accumulated safety alerts covering respiratory depression, misuse potential, withdrawal, psychiatric effects, pregnancy risks, and more. The sheer range of these warnings reflects both the drug’s rising popularity and a growing understanding of how it behaves in real-world patients, not just in controlled trials.
How Pregabalin Works, in Brief
Pregabalin binds to a specific protein on voltage-gated calcium channels in the brain and spinal cord. By doing so, it dials down the release of several excitatory chemical messengers that neurons use to talk to each other. This calming of overactive nerve signaling is what makes pregabalin useful for seizures, nerve pain, and anxiety, but it also explains many of its side effects: drowsiness, dizziness, and cognitive blunting are all downstream consequences of dampening neural activity.1PubMed. Pregabalin pharmacology and its relevance to clinical practice The drug has no direct effect on the brain’s main inhibitory system (GABA), despite its name sounding like it should.2PubMed. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery
Respiratory Depression With Opioids
The most life-threatening warning around pregabalin concerns breathing. When taken alongside opioid painkillers, pregabalin can worsen respiratory depression, the dangerous slowing or stopping of breathing that causes most opioid overdose deaths. A controlled study found that pregabalin potentiated the respiratory depression caused by the opioid remifentanil, meaning the combination suppressed breathing more than either drug alone.3Anesthesiology. Pregabalin Has Analgesic, Ventilatory, and Cognitive Effects in Combination with Remifentanil Animal research has added another layer of concern: pregabalin appeared to reverse the tolerance that builds up to oxycodone’s respiratory effects, which could mean that a person who has been on opioids for a while and adds pregabalin might suddenly become vulnerable to breathing problems they had previously adapted to.4PubMed Central. Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition
This is not a theoretical problem. Prescribing data from Australian general practice found high rates of same-day prescribing of pregabalin alongside opioids and benzodiazepines, a combination that puts patients at increased risk of harm.5BJGP Open. Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study The U.S. FDA added a boxed warning to gabapentinoid labels in 2019 specifically about this risk. If you take pregabalin and any opioid, benzodiazepine, or other central nervous system depressant, your prescriber should be actively monitoring for signs of slowed breathing, excessive sedation, or confusion.
Misuse, Dependence, and Withdrawal
Pregabalin was long considered to have low abuse potential, and in many countries it was originally sold as a regular prescription without controlled-substance scheduling. That view has shifted considerably. A systematic review found that pregabalin appeared somewhat more addictive than its cousin gabapentin, producing stronger dependence symptoms and more frequent transitions from prescribed use to self-administration, particularly among people with a history of substance use disorders.6PubMed. How addictive are gabapentin and pregabalin? A systematic review Animal research has shown that higher doses of pregabalin can produce rewarding effects in the brain, and this is consistent with clinical reports of euphoria as a side effect in trials.7Scientific Reports. Pregabalin: Potential for Addiction and a Possible Glutamatergic Mechanism
The withdrawal side of this equation is also underappreciated. You do not need to be a high-dose recreational user to experience withdrawal. Case reports have documented withdrawal symptoms in patients without psychiatric disorders who were taking regular prescribed doses of pregabalin and then stopped abruptly. Symptoms included insomnia, anxiety, and other psychiatric disturbances.8PubMed Central. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review In more extreme cases involving high doses or polydrug use, withdrawal has looked remarkably similar to benzodiazepine withdrawal: agitation, confusion, tachycardia, sweating, tremor, and in severe instances, auditory hallucinations and suicidal thoughts.9Southwest Journal of Pulmonary and Critical Care. Acute Pregabalin Withdrawal: A Case Report and Review of the Literature The practical takeaway is clear: never stop pregabalin cold turkey. Even if you are on a modest dose, taper gradually under medical supervision.
Psychiatric Effects and Suicidality
All antiepileptic drugs, pregabalin included, carry an FDA-mandated warning about increased risk of suicidal thoughts and behavior. While this class-wide warning is based on pooled analyses rather than pregabalin-specific data, individual case reports have described severe depressive episodes emerging during pregabalin therapy. One published case involved a 20-year-old man with no prior psychiatric history who developed a severe depressive syndrome while taking pregabalin, which escalated to a suicide attempt.10PubMed Central. Depression and attempted suicide under pregabalin therapy Case reports cannot prove causation, but they are the reason regulators recommend monitoring for new or worsening mood symptoms, especially early in treatment or after dose changes.
This warning creates an awkward paradox: pregabalin is prescribed for anxiety disorders in much of Europe, and anxiety itself is a risk factor for depression and suicidal thinking. Untangling drug effect from underlying illness is genuinely difficult. Still, if you or someone you know starts feeling noticeably worse emotionally after beginning pregabalin, that warrants an urgent conversation with a doctor rather than the assumption that the underlying condition is simply getting worse.
Pregnancy Risks
The evidence on pregabalin and birth defects is more nuanced than the prescribing label might suggest. An early crude analysis found that about 6% of infants exposed to pregabalin in the first trimester had major malformations compared to about 3% of unexposed infants. But after adjusting for other factors, the increased risk largely disappeared. When looking at pregabalin monotherapy, the pooled risk estimate was essentially the same as background rates.11PubMed Central. Pregabalin use early in pregnancy and the risk of major congenital malformations That study’s authors noted their findings did not confirm a teratogenic effect, though they could not entirely rule out a small one.
A larger Nordic population study found a similar pattern for malformations: an adjusted prevalence ratio of about 1.14, which was not statistically significant. However, that same study did flag a potential signal for stillbirth, with an adjusted ratio of about 1.72 among pregabalin-exposed pregnancies compared to unexposed ones, though this finding weakened in sensitivity analyses.12PubMed Central. Prenatal exposure to pregabalin, birth outcomes and neurodevelopment – a population-based cohort study in four Nordic countries Given this uncertainty, most prescribers treat pregabalin as something to avoid during pregnancy when possible, while acknowledging that for some women with severe epilepsy or pain, the risk of stopping may outweigh the risk of continuing. This is a conversation to have with a specialist, not a decision to make based on a warning label alone.
Weight Gain
Weight gain is one of the most common complaints among people taking pregabalin long-term, and the clinical data backs that up. A study following veterans treated for neuropathy found that those on pregabalin gained an average of about 3.6 pounds over 12 months, compared to a slight weight loss in those on duloxetine. When doses were increased, the pregabalin group gained an average of 6.5 pounds, a statistically significant difference.13PubMed Central. Weight Gain in Veterans Taking Duloxetine, Pregabalin, or Both for the Treatment of Neuropathy A year-long open-label safety study of pregabalin for anxiety disorders found that roughly a quarter of all participants experienced treatment-related weight gain.14PubMed. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
The mechanism is not fully pinned down, but the combination of increased appetite and fluid retention likely contributes. For people already managing diabetes or metabolic syndrome, both of which are common among pregabalin patients with neuropathy, this side effect has real clinical consequences. It is worth discussing weight monitoring with your prescriber from the outset, rather than discovering the problem 6 months in.
Peripheral Edema and Heart Failure
Swelling in the legs and feet is a well-known pregabalin side effect, but what gets less attention is how this can sometimes escalate to acute heart failure. A pharmacovigilance study that combined safety reports with animal experiments found that the median time to onset for non-cardiogenic edema was about 23 days, while acute heart failure tended to show up even sooner, at a median of about 17 days. The majority of cases occurred after a dose increase. The good news is that symptoms typically resolved within about a week of stopping the drug.15PubMed. Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments The patients most affected tended to be older, with a median age of 77 and a female-to-male ratio of about 4 to 1.
If you notice new swelling in your ankles or feet, or unexpected shortness of breath or rapid weight gain after starting pregabalin or increasing your dose, bring it up with your doctor promptly. For people with pre-existing heart conditions, this side effect may be a reason to choose a different medication altogether.
Older Adults, Kidney Function, and Fall Risk
Pregabalin is cleared almost entirely through the kidneys. For younger people with normal kidney function, this is straightforward. But kidney function declines naturally with age, and many older adults taking pregabalin for conditions like diabetic neuropathy already have some degree of kidney impairment. When the kidneys cannot clear pregabalin efficiently, the drug accumulates in the body and can produce neurotoxicity: confusion, severe drowsiness, unsteadiness, and sometimes myoclonus (involuntary jerking movements).16Journal of Population Therapeutics and Clinical Pharmacology. WHEN A SAVIOUR BECOMES THE CULPRIT: PREGABALIN-INDUCED NEUROTOXICITY IN AN ELDERLY PATIENT WITH DIABETIC KIDNEY DISEASE: A CASE REPORT IN CENTRAL INDIA Dose adjustment based on kidney function is mandatory but frequently overlooked in practice.
Even without kidney problems, advanced age is itself a risk factor for pregabalin-related balance disorders, weakness, and constipation.17PubMed Central. Pregabalin induced balance disorder, asthenia, edema, and constipation in an elderly adult: A case report Dizziness and unsteadiness translate directly into fall risk, and in older adults falls can mean broken bones, hospitalizations, and cascading health decline. If you are over 65 and your doctor prescribes pregabalin, ask specifically whether your kidney function has been checked recently and whether the dose has been adjusted accordingly.
Cognitive Effects and Driving
Drowsiness and dizziness are among the most frequently reported pregabalin side effects. Prescribing labels warn against driving or operating heavy machinery until you know how the drug affects you. Interestingly, a driving simulator study in healthy volunteers found no statistically significant impairment in core driving performance with pregabalin compared to placebo. However, the pregabalin group did not show the improvement in steering-wheel skills that the placebo group showed with practice, suggesting a subtle blunting of motor learning even when overt performance looks acceptable.18PubMed Central. Evaluation of the effect of pregabalin on simulated driving ability using a driving simulator in healthy male volunteers In real-world conditions, where unpredictable situations demand quick adaptation, that kind of reduced learning could matter more than it does on a simulator.
The cognitive effects extend beyond driving. Many patients describe a “brain fog” that includes difficulty concentrating, word-finding problems, and feeling mentally sluggish. These tend to be most pronounced when starting the drug or increasing the dose and may improve with time, but for some people they persist throughout treatment.
Skin Reactions
Allergic skin reactions to pregabalin are considered rare but can be surprisingly delayed. A published case described a 72-year-old man who developed a widespread rash covering roughly 80-90% of his body surface, but not until 40 days after starting pregabalin. The delayed onset made it harder to identify pregabalin as the culprit, and the reaction was only confirmed through a drug provocation test.19PubMed Central. Pregabalin-induced delayed cutaneous hypersensitivity reaction occurring after 40 days of use: a case report The clinical lesson here is that a new rash deserves scrutiny even if you have been on pregabalin for weeks without trouble.
Pregabalin Versus Gabapentin
Since pregabalin and gabapentin are close pharmacological relatives, many patients and prescribers wonder whether one is safer than the other. A meta-analysis of randomized trials comparing the two for postherpetic neuralgia found that pregabalin was more effective at relieving pain and improving sleep, but gabapentin was associated with fewer adverse events overall.20PubMed Central. A Meta-analysis of Randomized Controlled Trials Comparing the Efficacy and Safety of Pregabalin and Gabapentin in the Treatment of Postherpetic Neuralgia As noted earlier, systematic reviews also suggest pregabalin carries somewhat more misuse potential than gabapentin. The choice between the two often comes down to a trade-off between greater pain relief and a less favorable side-effect profile.
What Happens in Overdose
Pregabalin overdose, while serious, tends to be less immediately dangerous than overdose with opioids or benzodiazepines when taken alone. A study examining the dose-toxicity relationship found that the most common symptoms in pregabalin-only overdose were drowsiness, confusion, and apathy. The majority of cases produced only mild poisoning severity scores. Those with more significant toxicity had taken substantially higher doses per kilogram of body weight.21PubMed Central. Pregabalin poisoning: Evaluation of dose‐toxicity relationship The picture changes dramatically when pregabalin is combined with other depressants. Most deaths attributed to pregabalin involve co-ingestion of opioids, alcohol, or benzodiazepines rather than pregabalin alone.
Off-Label Prescribing and Why It Matters for Warnings
A significant share of pregabalin prescriptions are for conditions it was never formally approved to treat. Australian general practice data found that only about half of patients prescribed pregabalin had a recorded diagnosis of neuropathic pain, the sole approved indication for government subsidy in that country.22BJGP Open. Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study Off-label use is not inherently wrong, but it means many patients are exposed to the drug’s full range of risks for conditions where the evidence of benefit may be thinner. When the risk-benefit calculation is less clear, warnings become more consequential.
How Countries Have Responded
The accumulation of misuse data has prompted regulatory action in several countries, and the results offer a natural experiment in how scheduling affects prescribing. The UK reclassified pregabalin as a Class C controlled substance in April 2019. Following this, new pregabalin prescriptions began declining by about 3.4% per month, and the overall number of patients on the drug started dropping by about 4.2% per month soon after.23The Lancet Regional Health – Europe. Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study France introduced tighter prescribing rules, and saw an immediate and sustained drop in pregabalin dispensing along with a significant decrease in co-dispensing with opioids and benzodiazepines.24International Journal of Drug Policy. National impact of a constraining regulatory framework on pregabalin dispensations in France, 2020–2022
Egypt’s experience was the most dramatic: reclassifying pregabalin as a controlled substance led to a 99% drop in pregabalin sales, but gabapentin sales surged by nearly 600% over the following year.25PubMed Central. Impact of pregabalin reclassification as a controlled substance in Egypt on gabapentinoid and opioid utilization: A repeated cross-sectional study The substitution effect is a reminder that controlling one gabapentinoid without addressing the other may simply shift the problem rather than solve it.
Pediatric Use
Pregabalin is not widely approved for children, and the limited data available underscores why caution is warranted. A phase 1 trial in children with refractory partial seizures found that the most common side effects were sleepiness (affecting about 27% of pregabalin-treated children) and dizziness (about 13%). Four children on pregabalin discontinued treatment, with three of the four receiving the highest tested dose. Children weighing less than about 66 pounds cleared the drug roughly 43% faster per kilogram than adults, meaning standard adult dosing would be inappropriate.26Wiley Online Library (Epilepsia). Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study The faster clearance means children may need different weight-based dosing, but it also means the margin for error in dosing is narrower and side effects can appear quickly at doses that seem modest by adult standards.